Baragetti A, Ramirez G A, Magnoni M, Garlaschelli K, Grigore L, Berteotti M, Scotti I, Bozzolo E, Berti A, Camici P G, Catapano A L, Manfredi A A, Ammirati E, Norata G D
Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy; Center for the Study of Atherosclerosis - Bassini Hospital, Cinisello Balsamo, Italy.
Università Vita-Salute San Raffaele, Milan, Italy; Unit of Medicine and Clinical Immunology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Nutr Metab Cardiovasc Dis. 2018 Jan;28(1):53-63. doi: 10.1016/j.numecd.2017.09.001. Epub 2017 Sep 18.
Patients with Systemic Lupus Erythematosus (SLE) present increased cardiovascular mortality compared to the general population. Few studies have assessed the long-term development and progression of carotid atherosclerotic plaque in SLE patients. Our aim was to investigate the association of clinical and laboratory markers of disease activity and classical cardiovascular risk factors (CVRF) with carotid atherosclerosis development in SLE patients in a prospective 5-year study.
Clinical history and information on principal CVRFs were collected at baseline and after 5 years in 40 SLE patients (36 women, mean age 42 ± 9 years; 14.4 ± 7 years of mean disease duration) and 50 age-matched controls. Carotid Doppler ultrasonography was employed to quantify the atherosclerotic burden at baseline and at follow up. Clinimetrics were applied to assess SLE activity over time (SLEDAI). The association between basal circulating T cell subsets (including CD4CCR5; CD4CXCR3; CD4HLADR; CD4CD45RARO, CD4CD45RORA and their subsets) and atherosclerosis development was evaluated. During the 5-year follow up, 32% of SLE patients, developed carotid atherosclerosis compared to 4% of controls. Furthermore, considering SLEDAI changes over time, patients within the highest tertile were those with increased incidence of carotid atherosclerosis independently of CVRF. In addition, increased levels of CD4CCR5 T cells were independently associated with the development of carotid atherosclerosis in SLE patients.
Serial clinical evaluations over time, rather than a single point estimation of disease activity or CVRF burden, are required to define the risk of carotid atherosclerosis development in SLE patients. Specific T cell subsets are associated with long-term atherosclerotic progression and may further be of help in predicting vascular disease progression.
与普通人群相比,系统性红斑狼疮(SLE)患者的心血管疾病死亡率更高。很少有研究评估SLE患者颈动脉粥样硬化斑块的长期发展和进展情况。我们的目的是在一项为期5年的前瞻性研究中,调查疾病活动的临床和实验室指标以及经典心血管危险因素(CVRF)与SLE患者颈动脉粥样硬化发展之间的关联。
收集了40例SLE患者(36例女性,平均年龄42±9岁;平均病程14.4±7年)和50例年龄匹配的对照者在基线时和5年后的临床病史及主要CVRF信息。采用颈动脉多普勒超声在基线和随访时量化动脉粥样硬化负担。应用临床计量学评估随时间变化的SLE活动度(SLEDAI)。评估基础循环T细胞亚群(包括CD4CCR5、CD4CXCR3、CD4HLADR、CD4CD45RARO、CD4CD45RORA及其亚群)与动脉粥样硬化发展之间的关联。在5年的随访期间,32%的SLE患者出现了颈动脉粥样硬化,而对照组为4%。此外,考虑到SLEDAI随时间的变化,最高三分位数内的患者是颈动脉粥样硬化发生率增加的患者,且与CVRF无关。另外,CD4CCR5 T细胞水平升高与SLE患者颈动脉粥样硬化的发展独立相关。
需要对SLE患者进行随时间的系列临床评估,而不是对疾病活动度或CVRF负担进行单点估计,以确定颈动脉粥样硬化发展的风险。特定的T细胞亚群与长期动脉粥样硬化进展相关,可能有助于预测血管疾病的进展。